PMID- 27161651
OWN - NLM
STAT- MEDLINE
DCOM- 20170911
LR  - 20181202
IS  - 1440-1681 (Electronic)
IS  - 0305-1870 (Linking)
VI  - 43
IP  - 8
DP  - 2016 Aug
TI  - Cytoprotective effects of endothelin-1 on mesenchymal stem cells: an in vitro 
      study.
PG  - 769-76
LID - 10.1111/1440-1681.12590 [doi]
AB  - Stem cell-based therapies is a promising approach for regenerative therapy in 
      various diseases. Some obstacles remain to be solved before clinical application 
      of the cell therapy is realized, including increasing the survival of 
      transplanted stem cells, reducing loss of transplanted cells, and maintaining 
      adequate vascular supply. Recently, stem cell preconditioning with chemical and 
      pharmacological agents has been shown to increase therapeutic efficacy. The 
      present study investigated the effect of endothelin-1 (ET-1) on survival, 
      angiogenesis, and migration of mesenchymal stem cells (MSCs), in vitro. MSCs were 
      treated with various concentrations of ET-1 and the expression of 
      cyclooxygenase-2 (COX-2), hypoxia-inducible factor-1 (HIF-1), C-X-C chemokine 
      receptor type 4 (CXCR4), C-C chemokine receptor type 2 (CCR2), vascular 
      endothelial growth factor (VEGF), angiopoietin-2 (Ang-2), angiopoietin-4 (Ang-4) 
      and matrix metalloproteinase-2 (MMP-2) were examined. Caspase 3 activity and 
      prostaglandin E2 (PGE2) were determined by ELISA assay. MSCs migration and tube 
      formation potential were assessed using scratch test and three dimensional vessel 
      formation assay. ET-1 enhanced the MSCs viability. In ET-1- treated MSCs, 
      expression of COX-2, HIF-1, CXCR4, CCR2, VEGF, Ang-2, Ang-4 and MMP-2 were 
      increased compared to control groups. Elevation of all these genes were reversed 
      by celecoxib (50 mumol/L), a selective COX-2 inhibitor. PGE2 generation, MSCs 
      migration and tube formation were enhanced by ET-1 conditioning, whereas 
      caspase-3 activity was reduced in these cells, compared to the control group. The 
      results presented here reveal that preconditioning of MSCs with ET-1 has strong 
      cytoprotective effects through activation of survival signalling molecules and 
      trophic factors.
CI  - (c) 2016 John Wiley & Sons Australia, Ltd.
FAU - Pourjafar, Mona
AU  - Pourjafar M
AD  - Research Centre for Molecular Medicine, Hamadan University of Medical Sciences, 
      Hamadan, Iran.
FAU - Saidijam, Massoud
AU  - Saidijam M
AD  - Research Centre for Molecular Medicine, Hamadan University of Medical Sciences, 
      Hamadan, Iran.
FAU - Mansouri, Kamran
AU  - Mansouri K
AD  - Medical Biology Research Centre, Kermanshah University of Medical Sciences, 
      Kermanshah, Iran.
FAU - Malih, Sara
AU  - Malih S
AD  - Research Centre for Molecular Medicine, Hamadan University of Medical Sciences, 
      Hamadan, Iran.
FAU - Ranjbar Nejad, Tayebeh
AU  - Ranjbar Nejad T
AD  - Research Centre for Molecular Medicine, Hamadan University of Medical Sciences, 
      Hamadan, Iran.
FAU - Shabab, Nooshin
AU  - Shabab N
AD  - Research Centre for Molecular Medicine, Hamadan University of Medical Sciences, 
      Hamadan, Iran.
FAU - Najafi, Rezvan
AU  - Najafi R
AD  - Research Centre for Molecular Medicine, Hamadan University of Medical Sciences, 
      Hamadan, Iran.
AD  - Endometrium and Endometriosis Research Centre, Hamadan University of Medical 
      Sciences, Hamadan, Iran.
LA  - eng
SI  - GENBANK/NM_001106526
SI  - GENBANK/NM_001287107
SI  - GENBANK/NM_017232
SI  - GENBANK/NM_021866
SI  - GENBANK/NM_022205
SI  - GENBANK/NM_024359
SI  - GENBANK/NM_031054
SI  - GENBANK/NM_134454
SI  - GENBANK/NR_046237
PT  - Journal Article
PL  - Australia
TA  - Clin Exp Pharmacol Physiol
JT  - Clinical and experimental pharmacology & physiology
JID - 0425076
RN  - 0 (Endothelin-1)
SB  - IM
MH  - Animals
MH  - Cell Proliferation/drug effects/physiology
MH  - Cell Survival/*drug effects/physiology
MH  - Cells, Cultured
MH  - Cytoprotection/*drug effects/physiology
MH  - Dose-Response Relationship, Drug
MH  - Endothelin-1/*pharmacology
MH  - Human Umbilical Vein Endothelial Cells/drug effects/physiology
MH  - Humans
MH  - Male
MH  - Mesenchymal Stem Cells/*drug effects/physiology
MH  - Rats
MH  - Rats, Wistar
OTO - NOTNLM
OT  - cyclooxygenase-2
OT  - endothelin-1
OT  - mesenchymal stem cells
OT  - prostaglandin E2
OT  - stem cell therapy
EDAT- 2016/05/11 06:00
MHDA- 2017/09/12 06:00
CRDT- 2016/05/11 06:00
PHST- 2016/02/10 00:00 [received]
PHST- 2016/05/02 00:00 [revised]
PHST- 2016/05/04 00:00 [accepted]
PHST- 2016/05/11 06:00 [entrez]
PHST- 2016/05/11 06:00 [pubmed]
PHST- 2017/09/12 06:00 [medline]
AID - 10.1111/1440-1681.12590 [doi]
PST - ppublish
SO  - Clin Exp Pharmacol Physiol. 2016 Aug;43(8):769-76. doi: 10.1111/1440-1681.12590.